client logo
Version: 1.0.0 | Published: 7 Oct 2026 | Updated: 42 days ago

Evaluating the Genetic Factors Associated with Non-Alcoholic Steatohepatitis

Dataset

Documentation

Description:
Steatotic disease can be triggered by a combination of excess alcohol, dysmetabolism and lifestyle factors, which can lead to steatohepatitis and can progress to acute/chronic liver failure and hepatocellular carcinoma. To date, there are no approved drugs for treating MASLD, MetALD or ALD. A multifaceted etiopathogenesis, lack of reproducible animal models that effectively recreate human MASLD, and lack of robust surrogate trial endpoints have presented major hurdles in drug discovery and development . New biomarkers identified/established through this study will address this problem providing non-invasive surrogate indicators of disease severity to use as end points in clinical trials. By developing a large deeply-phenotyped cohort with follow up over 10 years and investigating both genetic and mechanistic disease biomarkers, a greater understanding of the interplay between factors and pathways will be of value for refinement of therapeutic pipelines. Thus, this will pave the way for precision medicine approaches to tackle this prevalent disease. Comparing the features of people with fatty liver (NASH/ASH) to those of people with no disease with the aim to develop new non-invasive tests to diagnose fatty liver disease, NASH/ASH and predict disease progression, as an alternative to liver biopsy. Case-control, prospective, observational, multi-centre study: ‘Cases’: Adult patients with diagnosed steatotic liver diseases [can be non-alcoholic fatty liver disease (NAFLD), recently re-defined as metabolic dysfunction-associated steatotic liver disease (MASLD) and ‘MASLD with increased alcohol intake’ (Met-ALD) or alcohol-related liver disease (ALD)]. ‘Controls’: adults without liver disease . To evaluate the role of genetic polymorphisms in susceptibility and development, of non-alcoholic steatohepatitis and alcoholic steatohepatitis and their correlation with potential non-invasive biomarkers. Overview of Demographic and clinical data collected (where applicable). Demographics: Age at visit, Sex at birth, Self-reported ethnicity Anthropometrics: Height, Weight, Waist circumference, grip strength, arm fat Health status: Diabetes mellitus diagnosis, Presence of hypertension, Smoking status (cigarettes per week), Alcohol intake (g per week), Current pregnancy, recreational drug use. Lifestyle Questionnaires EPIC FFQ & IPAQ Liver episode: Detection date, Symptoms, Drug/Supplement treatments, Whether biopsy was done, Outcome Results of routine clinical investigations: Haematology, Clinical Biochemistry, Immunology, and Liver function Total protein, Albumin, Transferrin, Ceruloplasmin, C-reactive protein Glucose, Insulin, HbA1c Prothrombin time, International normalised ratio. Urea, Creatinine, Sodium, Potassium. Alanine transaminase (ALT), Aspartate transaminase (AST), Gamma glutamyl transferase (GGT), Alkaline phosphatase (ALP), Total bilirubin (TBL), Conjugated bilirubin. Iron, Ferritin. Thyroid-stimulating hormone Lactate dehydrogenase, Creatine kinase, Creatine kinase-MB. Cholesterol, Low-density lipoprotein, High-density lipoprotein, Triglycerides Haemoglobin, Platelets, Erythrocytes, Leukocytes, Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils Clinical imaging results: Transient elastography, ultrasound Clinical tests to support diagnosis (routine diagnostics or local practice for clinical care or research): Viral serology tests, Autoantibody serology. Immunoglobulin levels. Histological findings for any biopsy performed. Extended clinical Information including follow-up information for diagnosis. Co-morbidities (past and current), Concomitant medications, herbal and/or dietary supplements, Past alcohol history, Outcomes. Omics assay: 16S and sequencing of microbiome

Coverage

Spatial:
England; Scotland
Typical Age Range:
18-150
Follow Up:
1 - 10 Years

Provenance

Origin

Purposes:
Study
Sources:
Other
Collection Situations:
Other

Temporal

Accrual Periodicity:
Irregular
Distribution Release Date:
08 October 2024
Start Date:
05 May 2021
Time Lag:
Variable

Accessibility

Access

Access Rights:
In progress
Delivery Lead Time:
Variable
Jurisdictions:
UK
Data Controller:
Nottingham University Hospitals NHS Trust
Data Processor:
Dr Jane Grove; Professor Guruprasad Aithal

Usage

Data Use Limitations:
User-specific restrictions
Data Use Requirements:
User-specific restriction
Resource Creators:
To be confirmed

Format and Standards

Vocabulary Encoding Schemes:
LOCAL
Conforms To:
LOCAL
Languages:
en
Formats:
  • tab-delimited text
  • csv
  • Excel
  • CDSIC ODM XML
  • CDISC Transactional ODP XML
  • SAS
  • JSON

Observations

Statistical Population
Population Description
Population Size
Measured Property
Observation Date
Persons
930
Count
17 July 2026